Immunosuppression in clinical practice: AAApproaches to individualized therapy

Andrew Chan, Olaf Stüve, Nicolas Von Ahsen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalJournal of Neurology
Volume255
Issue numberSUPPL. 6
DOIs
StatePublished - Dec 2008

Fingerprint

Immunosuppressive Agents
Immunosuppression
Pharmacogenetics
Metabolic Networks and Pathways
Therapeutics
Pharmaceutical Preparations

Keywords

  • Azathioprine
  • Cyclophosphamide
  • Methotrexate
  • Mitoxantrone
  • Pharmacogenetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Immunosuppression in clinical practice : AAApproaches to individualized therapy. / Chan, Andrew; Stüve, Olaf; Von Ahsen, Nicolas.

In: Journal of Neurology, Vol. 255, No. SUPPL. 6, 12.2008, p. 22-27.

Research output: Contribution to journalArticle

Chan, Andrew ; Stüve, Olaf ; Von Ahsen, Nicolas. / Immunosuppression in clinical practice : AAApproaches to individualized therapy. In: Journal of Neurology. 2008 ; Vol. 255, No. SUPPL. 6. pp. 22-27.
@article{88af9a66315b467e95cae2d78014b570,
title = "Immunosuppression in clinical practice: AAApproaches to individualized therapy",
abstract = "Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.",
keywords = "Azathioprine, Cyclophosphamide, Methotrexate, Mitoxantrone, Pharmacogenetics",
author = "Andrew Chan and Olaf St{\"u}ve and {Von Ahsen}, Nicolas",
year = "2008",
month = "12",
doi = "10.1007/s00415-008-6005-y",
language = "English (US)",
volume = "255",
pages = "22--27",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Immunosuppression in clinical practice

T2 - AAApproaches to individualized therapy

AU - Chan, Andrew

AU - Stüve, Olaf

AU - Von Ahsen, Nicolas

PY - 2008/12

Y1 - 2008/12

N2 - Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

AB - Despite novel immunoactive agents, immunosuppressants still play a considerable role in the treatment of MS, especially in rapidly progressive cases. Given the limited tolerability and potentially severe side effects of most immunosuppressive drugs, identification of patients with a favorable benefit-risk profile is essential. A narrow therapeutic index, with sometimes high interindividual variability in terms of response and side effects may partially be explained by genetic factors affecting different metabolic pathways. Here, we will review practical aspects in the clinical use of immunosuppressants in MS and discuss approaches to individualized treatment schemes, including novel pharmacogenetic strategies.

KW - Azathioprine

KW - Cyclophosphamide

KW - Methotrexate

KW - Mitoxantrone

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=64149123239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149123239&partnerID=8YFLogxK

U2 - 10.1007/s00415-008-6005-y

DO - 10.1007/s00415-008-6005-y

M3 - Article

C2 - 19300956

AN - SCOPUS:64149123239

VL - 255

SP - 22

EP - 27

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - SUPPL. 6

ER -